Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals (MIRM) will host an investor call on October 12, 2026, to share topline results from the Phase 3 EXPAND study.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif.--(BUSINESS WIRE)--

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI^® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.

Conference Call Details:

US/Toll-Free: +1 833 461 5787
International: +1 585 542 9983
Access Code: 486697901

You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI^® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), ATEBRIOZ™ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM^® (cholic acid) for bile-acid synthesis disorders and CTEXLI^® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261011330842/en/

Investor Contact:
Andrew McKibben
ir@mirumpharma.com

Media Contact:
Meredith Kiernan
media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

Key Terms

cholestatic pruritus medical

Severe itching caused by impaired bile flow from the liver into the gut, where substances that normally leave the body build up and irritate nerve endings in the skin. Investors should care because this symptom can drive demand for treatments, shape clinical trial measures and regulatory decisions, and affect a drug’s safety profile and market potential—much like a visible fault that influences customer trust and product value.

biliary atresia medical

Biliary atresia is a rare, serious condition in newborns where the tiny tubes that carry bile from the liver to the intestine are missing or blocked, like plumbing pipes that never formed or become sealed. Without bile flow, the liver is damaged over time, often requiring surgery or transplant. For investors, it matters because treatments, surgical techniques, and long-term care represent focused medical markets, regulatory pathways, and potential clinical-trial milestones.